Tirzepatide

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This first-in-class twincretin molecule combines the metabolic benefits of both incretin pathways, demonstrating superior efficacy in clinical trials compared to selective GLP-1 agonists.

Tirzepatide engages both GIP and GLP-1 receptors with a relative activity ratio favoring GIP. GIP receptor activation in adipose tissue enhances lipid buffering capacity. Simultaneous GLP-1R activation provides appetite suppression and glucose-dependent insulin secretion.

Peak plasma concentration occurs approximately 8-72 hours post-injection. Terminal half-life is approximately 5 days, supporting weekly administration.

Note: These are research protocols from literature. This is not medical advice.

Peptides that may be combined based on complementary mechanisms in research settings.

• 1SURMOUNT-1 trial demonstrated 22.5% mean weight loss with 15mg dose over 72 weeks
• 2SURPASS trials showed HbA1c reductions up to 2.4%, superior to semaglutide 1mg
• 3Significant reductions in waist circumference, blood pressure, and lipid parameters
• 4Phase 3 MASH trials showing histological improvement in liver fibrosis

Refrigerate at 2-8C until first use. May keep at room temperature for up to 21 days.

Scientific References

• 1
  Tirzepatide Once Weekly for the Treatment of Obesity

  Jastreboff AM, et al.

  NEJM, 2022 | DOI: 10.1056/NEJMoa2206038